SCHEMBL2325751

SCHEMBL2325751

CCC[C@@H](OS(=O)(=O)c1ccc(C)cc1)C(=O)O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 1/20 0.44
CA2 P00918 1/20 0.44
CA9 Q16790 1/20 0.44
PPARG P37231 5/20 0.41
PPARA Q07869 4/20 0.41
STAT3 P40763 1/20 0.40
MMP2 P08253 2/20 0.40
MMP9 P14780 2/20 0.40
PTGDR2 Q9Y5Y4 1/20 0.39
SLC1A3 P43003 1/20 0.38
SLC1A2 P43004 1/20 0.38
SLC1A1 P43005 1/20 0.38
GAA P10253 1/20 0.38
KMT2A Q03164 1/20 0.38
ALDH1A1 P00352 2/20 0.38
RECQL P46063 1/20 0.38
MMP1 P03956 1/20 0.38
MMP3 P08254 1/20 0.38
MMP7 P09237 1/20 0.38
MMP13 P45452 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10572149 1.00 CA12 (0.44) CA12CA2CA9PPARGPPARA
SCHEMBL2328962 0.91 PPARG (0.42) CA12CA2CA9PPARGPPARA
SCHEMBL9458215 0.89 CTRC (0.48) CA12CA2CA9PPARGPPARA
SCHEMBL10809966 0.89 CTRC (0.48) CA12CA2CA9PPARGPPARA
SCHEMBL3064836 0.88 SMN1; SMN2 (0.43) PPARGPPARASTAT3MMP2MMP9
SCHEMBL1990107 0.88 SMN1; SMN2 (0.43) PPARGPPARASTAT3MMP2MMP9
SCHEMBL7265141 0.88 SMN1; SMN2 (0.43) PPARGPPARASTAT3MMP2MMP9
SCHEMBL13369726 0.87 KMT2A (0.41) CA2PPARGSTAT3MMP9SLC1A3
SCHEMBL14058877 0.85 CA2 (0.42) CA12CA2CA9PPARGSTAT3
SCHEMBL9306403 0.83 KDM4E (0.44) PPARGPPARASTAT3MMP2MMP9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8338621-B2 Process for the preparation of 2-oxo-1-pyrrolidine derivatives UCB S.A. (BE) 2012-12-25 US disclosed
EP-1806339-B1 Process for the preparation of 2-oxo-1-pyrrolidine derivatives UCB PHARMA SA (BE) 2011-08-17 EP disclosed
US-20080009638-A1 PROCESS FOR THE PREPARATION OF 2-OXO-1-PYRROLIDINE DERIVATIVES UCB S.A. (BE) 2008-01-10 US disclosed
EP-1806339-A1 Process for the preparation of 2-oxo-1-pyrrolidine derivatives UCB, S.A. (BE) 2007-07-11 EP disclosed
US-7183308-B1 Metod for the synthesis of perindopril and the pharmaceutically acceptable salts thereof LES LABORATOIRES SERVIER (FR) 2007-02-27 US disclosed
US-20070043103-A1 NOVEL METOD FOR THE SYNTHESIS OF PERINDOPRIL AND THE PHARMACEUTICALLY-ACCEPTABLE SALTS THEREOF LES LABORATOIRES SERVIER (FR) 2007-02-22 US disclosed
EP-1380590-B1 Method for synthesis of perindopril and its pharmaceutically acceptable salts SERVIER LAB (FR) 2006-09-06 EP disclosed
EP-1380590-A1 Method for synthesis of perindopril and its pharmaceutically acceptable salts Les Laboratoires Servier (FR) 2004-01-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080009638-A1 PROCESS FOR THE PREPARATION OF 2-OXO-1-PYRROLIDINE DERIVATIVES CYP2F1, CYP3A5, SULT1E1 CA12 3778/4885CA2 1508/4885CA9 1434/4885
US-20070043103-A1 NOVEL METOD FOR THE SYNTHESIS OF PERINDOPRIL AND THE PHARMACEUTICALLY-ACCEPTABLE SALTS THEREOF ACE, REN, QDPR CA12 4851/4885CA2 3361/4885CA9 3347/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.